Effect of nisin and doxorubicin on DMBA-induced skin carcinogenesis—a possible adjunct therapy

Tumor Biology

Volumn 36, Issue 11, 2015, Pages 8301-8308

  Preet, Simran ^a   Bharati, Sanjay ^a   Panjeta, Anshul ^a   Tewari, Rupinder ^a   Rishi, Praveen ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Adjunct; Anti cancer peptide; Doxorubicin; Nisin; Skin cancer

Indexed keywords

CATALASE; DIMETHYLBENZ[A]ANTHRACENE; DOXORUBICIN; LIPID; MALONALDEHYDE; NISIN; NITRITE; SUPEROXIDE DISMUTASE; 3-(2,6-BIS(4-FLUOROPHENYL)-3-METHYLPIPERIDIN-4-YLIDENEAMINO)-2-THIOXOIMIDAZOLIDIN-4-ONE ON 7,12-DIMETHYLBENZ(A)ANTHRACENE; ANTHRACENE DERIVATIVE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER RESISTANCE; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; SKIN CANCER; TUMOR VOLUME; TUNEL ASSAY; ANIMAL; APOPTOSIS; CARCINOGENESIS; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; SKIN NEOPLASMS;

ANIMALS; ANTHRACENES; APOPTOSIS; CARCINOGENESIS; DOXORUBICIN; HUMANS; LIPID PEROXIDATION; MICE; NEOPLASMS, EXPERIMENTAL; NISIN; OXIDATIVE STRESS; PIPERIDINES; SKIN NEOPLASMS;

EID: 84949086515     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3571-3     Document Type: Article

References (27)

1. Kakde D, Jain D, Shrivastava V, Kakde R, Patil AT. Cancer therapeutics—opportunities, challenges and advances in drug delivery. J App Pharm Sci. 2011;1:1.
2. Aly A, Mullins CD, Hussain A. Understanding heterogeneity of treatment effect in prostate cancer. Curr Opin Oncol. 2015;27:209–16.
3. Busch CJ, Tribius S, Schafhausen P, Knecht R. The current role of systemic chemotherapy in the primary treatment of head and neck cancer. Cancer Treat Rev. 2015;41:217–21.
4. Coward JI, Middleton K, Murphy F. The new perspectives on targeted therapy in ovarian cancer. Int J Wom Health. 2015;7:189–03.
5. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta Biomembr. 2008;1778:357–75.
6. Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharm. 2009;625:190–4.
7. Bhutia SK, Maiti TK. Targeting tumours with peptides from natural sources. Trends Biotechnol. 2008;26:210–7.
8. Wei XQ, Ma HQ, Liu AH, Zhang YZ. Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells. Asian Pac J Cancer Prev. 2013;14:3023–8.
9. Sylvester PW, Wali VB, Bachawal SV, Shirode AB, Ayoub NM, Akl MR. Tocotrienol combination therapy results in synergistic anticancer response. Front Biosci (Landmark Ed). 2011;1:3183–95.
10. Jay JM. Modern Food Microbiology. 6th ed. Gaithersburg: Aspen Publishers Inc; 2000. p. 679.
11. Joo NE, Ritchie K, Kamarajan P, Miao D, Kapila YL. Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumourigenesis via CHAC1. Cancer Med. 2012;1:295–05.
12. Arora N, Koul A, Bansal MP. Chemopreventive activity of Azadirachta indica on two-stage skin carcinogenesis in murine model. Phytother Res. 2011;25:408–16.
13. Subapriya R, Nagini S. Medicinal properties of neem leaves: a review. Curr Med Chem Anti Cancer Agents. 2005;5:149–56.
14. Bharati S, Rishi P, Koul A. Azadirachta indica modulates electrical properties and type of cell death in NDEA-induced hepatic tumours. Cell Biochem Bioph. 2014;70:383–90.
15. Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem J. 1966;99:667–76.
16. Rishi P, Preet S, Bharrhan S, Verma I. In vitro and in vivo synergistic effects of cryptdin- 2 and ampicillin against Salmonella. Antimicrob Agents Chemother. 2011;55:4176–82.
17. Green LC et al. Analysis of nitrate, nitrite and 15N nitrate in biological fluids. Anal Biochem. 1982;126:131–8.
18. Luck H. Catalase. In: Bergmeyer HU, editor. Methods of enzymatic analysis. New York: Academic Press; 1963. p. 885–88.
19. Lowry OH, Rosenbrough NJ, Farr AL, Randell RJ. Protein measurement with Folin’s phenol reagent. J Biol Chem. 1951;193:265–75.
20. Diwan BA, Kasprzak KS, Anderson LM. Promotion of dimethylbenzanthracene-initiated mammary carcinogenesis by iron in female Sprague–Dawley rats. Carcinogenesis. 1997;18:1757–62.
21. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow–derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–90.
22. Padmavathi B, Upreti M, Singh V, Rao AR, Singh RP, Rath PC. Chemoprevention by Hippophae rhamnoides: effects on tumourigenesis, phase II and antioxidant enzymes, and IRF-1 transcription factor. Nutr Cancer. 2005;51(1):59–67.
23. Yokochi T, Robertson KD. Doxorubicin inhibits DNMT1 resulting in conditional apoptosis. Mol Pharmacol. 2004;66:1415–20.
24. Aldieri E, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D. Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation. Toxicol Appl Pharmacol. 2002;185:85–90.
25. Tamir S, Tannenbaum SR. The role of nitric oxide (NO) in the carcinogenic process. Biochim Biophys Acta. 1996;1288:F31–6.
26. Murphy MP. Nitric oxide and cell death. Biochim Biophys Acta. 1999;1411:401–14.
27. Bartoli GM, Galeotti T. Growth-related lipid peroxidation in tumour microsomal membranes and mitochondria. Biochimica et Biophysica Acta (BBA)—Lipids and Lipid. Metabolism. 1979;574:537–41.